Results 191 to 200 of about 120,942 (241)

Dopamine agonist-responsive Cushing's disease. [PDF]

BMJ Case Rep, 2019
Anand G, Bink A, Beuschlein F, Schmid C.
europepmc   +1 more source

Conclusion lessons from the novel D2 dopamine receptor, β2-adrenoceptor agonist, Viozan™: chronic obstructive pulmonary disease and drug development implications

, 2003
P. M. A. Calverley, E.T. Keating, Mitch Goldman, Frank E. Casty   +3 more
openalex   +1 more source

Early clinical investigation of Viozan™ (sibenadet HCI), a novel D2 dopamine receptor, β2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms

, 2003
P.W. Ind, L. A. Laitinen, L. Laursen, Sally E. Wenzel, E.F.M. Wouters, L. Deamer, P O Nyström   +6 more
openalex   +1 more source

Conclusion lessons from the novel D2 dopamine receptor, $beta;2-adrenoceptor agonist, Viozan?: chronic obstructive pulmonary disease and drug development implications

, 2003
P CALVERLEY
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dopamine Agonists

Seminars in Neurology, 2001
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire   +2 more sources